Using CHROMagar™ STEC medium exclusively does not recover all clinically relevant Shiga toxin-producing Escherichia coli in Aotearoa, New Zealand
Letters in Applied Microbiology · 2024
DOI: 10.1093/lambio/ovae033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Letters in Applied Microbiology, 2024. Verfasst von Lucia Rivas und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Environmental Science and Research (ESR), Christchurch Science Centre, 27 Creyke Road, Ilam, Christchurch 8041, New Zealand. Hauptthemen laut MEDLINE: Shiga-Toxigenic Escherichia coli, Escherichia coli Infections, Escherichia coli Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ESR Science Strategic Investment Fund.
Abstract (Originalsprache)
Diagnostic laboratories in Aotearoa, New Zealand (NZ) refer cultures from faecal samples positive for Shiga toxin genes to the national Enteric Reference Laboratory for isolation of Shiga toxin-producing Escherichia coli (STEC) for epidemiological typing. As there was variation in the culture media being referred, a panel of 75 clinical isolates of STEC, representing 28 different serotypes, was used to assess six commercially available media and provide guidance to clinical laboratories. Recommendations were subsequently tested for a 3-month period, where STEC isolations and confirmations were assessed by whole genome sequencing analysis against the culture media referred. CHROMagar™ STEC (CH-STEC; CHROMagar Microbiology, Paris, France) or CH-STEC plus cefixime-tellurite sorbitol MacConkey agar was confirmed inferior to CH-STEC plus blood agar with vancomycin, cefsulodin, and cefixime (BVCC). The former resulted in fewer STEC types (n = 18) being confirmed compared to those from a combination of CH-STEC and BVCC (n = 42). A significant (P < .05) association with an STEC’s ability to grow on CH-STEC and the presence of the ter gene cluster, and eae was observed. Culturing screen positive STEC samples onto both CH-STEC and BVCC ensures a consistently higher recovery of STEC from all clinical samples in NZ than CH-STEC alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Environmental Science and Research (ESR), Christchurch Science Centre, 27 Creyke Road, Ilam, Christchurch 8041, New Zealand.
- Institute of Environmental Science and Research (ESR), Wallaceville Science Centre, 66 Ward Street, Wallaceville, Upper Hutt 5018, New Zealand.
- Institute of Environmental Science and Research (ESR), Kenepuru Science Centre, 34 Kenepuru Drive, Kenepuru, Porirua 5022, New Zealand.
ORCID-Profile: Lucia Rivas, David Duncan, Jing Wang, Hilary Miller, Jackie Wright
Förderung
- ESR Science Strategic Investment Fund
Zitieren
APA
Rivas, L., Duncan, D., Wang, J., Miller, H., & Wright, J. (2024). Using CHROMagar™ STEC medium exclusively does not recover all clinically relevant Shiga toxin-producing Escherichia coli in Aotearoa, New Zealand. Letters in Applied Microbiology. https://doi.org/10.1093/lambio/ovae033
Vancouver
Rivas L, Duncan D, Wang J, Miller H, Wright J. Using CHROMagar™ STEC medium exclusively does not recover all clinically relevant Shiga toxin-producing Escherichia coli in Aotearoa, New Zealand. Letters in Applied Microbiology. 2024. doi:10.1093/lambio/ovae033
BibTeX
@article{Rivas2024,
author = {Rivas, Lucia and Duncan, David and Wang, Jing and Miller, Hilary and Wright, Jackie},
title = {Using CHROMagar™ STEC medium exclusively does not recover all clinically relevant Shiga toxin-producing Escherichia coli in Aotearoa, New Zealand},
journal = {Letters in Applied Microbiology},
year = {2024},
doi = {10.1093/lambio/ovae033}
}
EUVIMED